Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: The SMOOTH study

Journal of Hypertension

Volumn 24, Issue 5, 2006, Pages 837-843

  Mancia, Giuseppe ^a,b,h   Parati, Gianfranco ^a,b   Borghi, Claudio ^c   Ghironzi, Giuseppe ^d   Andriani, Egidio ^e   Marinelli, Liano ^f   Valentini, Mariaconsuelo ^a   Tessari, Francesco ^g   Ambrosioni, Ettore ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Società Sammarinese di Cardiologia   (San Marino)

^e Department of Obstetrics and Gynecology   (San Marino)

^f Unità di Cardiologia   (San Marino)

^g Centro Elaborazione Dati Idea 99   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive treatment; Epidemiology; Hypertension; Mediterranean diet; Metabolic factors; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AWARENESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SAN MARINO; SMOKING; SOUTHERN EUROPE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 33646350776     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000222752.67572.61     Document Type: Article

References (42)

1. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-183.
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
3. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997; 10:1097-1102.
4. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305-313.
5. Julius M, Harburg E, Cottington EM, Johnson EH. Anger-coping types, blood pressure, and all-cause mortality: a follow-up in Tecumseh, Michigan (1971-1983). Am J Epidemiol 1986; 124:220-233.
6. MacMahon SW, Blacket RB, Macdonald GJ, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertens 1984; 2:85-91.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
8. Mancia G, Grassi G. Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J 1999; 1:L14-L19.
9. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, Sega R. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002; 162:582-586.
10. Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD. Prevalence, awareness, treatment, and control of hypertension in Greece: the Didima study. Am J Hypertens 1999; 12:959-965.
11. Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, Gallois H, Cremier O. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998; 11:759-762.
12. Banegas JR, Rodriguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillon P, del Rey Calero J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998; 32:998-1002.
13. van Rossum CT, van de Mheen H, Witteman JC, Hofman A, Mackenbach JP, Grobbee DE. Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly. Hypertension 2000; 35:814-821.
14. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998; 80 (suppl 2):S1-S29.
15. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434-1503.
16. Kannel WB. Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Cardiol 1996; 77:6B-11B.
17. Menotti A, Lanti M, Zanchetti A, Puddu PE, Cirillo M, Mancini M, Vagnarelli OT. Impact of the GUBBIO population study on community control of blood pressure and hypertension. Gubbio Study Research Group. J Hypertens 2001; 19:843-850.
18. Descovich GC. The Brisighella Heart Study: an interim report. Eur Heart J 1990; 11 (suppl H):32-37.
19. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
20. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
21. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109:551-556.
22. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
23. Aster R. Professional SAS programming shortcuts. New York: Breakfast Communications; 2003.
24. Von Hafe P, Andrade MJ, Fernando PB, Lopes C, Maciel MJ, Coelho R, Barros H. Prevalence, knowledge, treatment and control of arterial hypertension in Oporto, Portugal. Rev Port Cardiol 1997; 16:683-690.
25. Strasser T. Hypertension: the east European experience. Am J Hypertens 1998; 11:756-758.
26. Meissner I, Whisnant JP, Sheps SG, Schwartz GL, O'Fallon WM, Covalt JL, et al. Detection and control of high blood pressure in the community: Do we need a wake-up call? Hypertension 1999; 34:466-467.
27. Rywik SL, Davis CE, Pajak A, Broda G, Folsom AR, Kawalec E, Williams OD. Poland and U.S. collaborative study on cardiovascular epidemiology hypertension in the community: prevalence, awareness, treatment, and control of hypertension in the Pol-MONICA Project and the U.S. Atherosclerosis Risk in Communities Study. Ann Epidemiol 1998; 8: 3-13.
28. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-1464.
29. Ruzicka M, Leenen FH. Combination therapy as first-line treatment of arterial hypertension. Can Cardiol 2002; 18:1317-1327.
30. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al. Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17:81-86.
31. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhou G, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342:1-8.
32. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21:1635-1640.
33. Stokes J, Kannel WB, Wolf PA, D'Agostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 1989; 13 (suppl I):I13-I18.
34. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140:199-270.
35. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
36. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
37. Nesbitt SD, Julius S. Prehypertension: a possible target for antihypertensive medication. Curr Hypertens Rep 2000; 2:356-361.
38. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
39. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
40. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, et al. Effects of blood pressure measurements by the doctor on the patient's blood pressure and heart rate. Lancet 1983; 2:695-698.
41. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
42. Ferrario M, Sega R, Chatenoud L, Mancia G, Mocarelli P, Crespi C, Cesana G. MONICA-Brianza Research Group. MONItoring of CArdiovascular diseases. Time trends of major coronary risk factors in a northern Italian population. How remarkable are socioeconomic differences in an industrialized low CHD incidence country? Int J Epidemiol 2001; 30:285-297.